Use of Parenteral Fish Oil to Reverse Cholestasis Induced by Parenteral Nutrition in Infants with Intestinal Failure: Single-Centre Case Series

Reniers, Denise; Rajakumar, Irina; Ratko, Suzanne; Atkison, Paul

doi:10.4212/cjhp.v65i1.1100

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The emulsifier in this lipid emulsion, based on glycerol and egg yolk phospholipid, is similar to that used in soybean IVFE. A number of case reports, case series, and retrospectively controlled trials of IV fish oil have been reported in infants with or at risk for IFALD 98 – 107 . No therapeutic or prophylactic double‐blind randomized controlled trials have been completed to demonstrate the efficacy of this therapy for this indication.…”

Section: Case Examplesmentioning

confidence: 99%

Scientific, Economic, Regulatory, and Ethical Challenges of Bringing Science‐Based Pediatric Nutrition Products to the U.S. Market and Ensuring Their Availability for Patients

Merritt

Goldsmith

2014

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Many nutrition products and related drugs are unavailable or not consistently available to clinicians despite a body of clinical data and experience supporting their use. Many of these can be related to drug shortages that have increased since 2009. In addition, there are potentially useful products that are not approved for a specific use or are no longer being manufactured. This review broadly examines the product availability gap from the perspectives of a clinician/former nutrition industry medical director and an economist. The process of pediatric nutrition product and related drug innovation, as well as its drivers and the steps involved in bringing a product to market, is first described. This is followed by an assessment of factors influencing product availability beyond the innovation process, including regulatory issues, manufacturing compliance, purchasing practices, and other factors related to drug and nutrition product pricing and reimbursement. Three pediatric case examples are reviewed and placed in the context of the prior review. Last, recent and future possible steps toward closing the product availability gap are discussed.

show abstract